Mabpharm Limited (Mabpharm-B) submitted its Monthly Return for Equity Issuer to Hong Kong Exchanges and Clearing for the period ended 30 April 2026, disclosing no changes in either authorised or issued share capital during the month.

Authorised Share Capital • Authorised share capital stayed at 50.00 billion ordinary shares with a par value of USD 0.0001 each, translating to USD 5.00 million in authorised capital.

Issued Shares and Public Float • Issued shares (excluding treasury shares) were unchanged at 4.12 billion. • The company held no treasury shares. • Mabpharm-B confirmed compliance with the Main Board’s minimum public-float threshold of 25 percent.

Share-Based Incentives • Outstanding options under the 10 August 2018 Share Option Scheme totalled 72.67 million, with no grants, exercises, lapses or cancellations recorded in April. • These options represent approximately 1.76 percent of current issued shares, should they be fully exercised. • No funds were raised through option exercises during the month.

Other Securities Instruments • The issuer reported no warrants, convertible securities, or other agreements that could lead to share issuance, and no repurchases or redemptions occurred.

Overall, Mabpharm-B’s capital structure remained static in April 2026, with stable issued equity and a modest option overhang of 72.67 million shares.